Skip to main content

LIMITED TIME MATCH: Donate TODAY to DOUBLE your impact.

showDesktop,showTablet,showMobile

Treatment Choices for Non-Small Cell Lung Cancer, by Stage

The treatment options for non-small cell lung cancer (NSCLC) are based mainly on the stage (extent) of the cancer, but other factors, such as a person’s overall health and lung function, as well as certain traits of the cancer itself, are also important.

If you smoke: One of the most important things you can do to be ready for treatment is to try to quit. Studies have shown that people who stop smoking after a diagnosis of lung cancer tend to have better outcomes than those who don’t.

Treating occult cancer

For these cancers, malignant cells are seen on sputum cytology, but no obvious tumor can be found with bronchoscopy or imaging tests. They are usually early-stage cancers. Bronchoscopy and possibly other tests are usually repeated every few months to look for a tumor. If a tumor is found, treatment will depend on the stage.

Treating stage 0 NSCLC

Because stage 0 NSCLC is limited to the lining layer of the airways and has not invaded deeper into the lung tissue or other areas, it is usually curable by surgery alone. No chemotherapy or radiation therapy is needed.

If you are healthy enough for surgery, you can usually be treated by segmentectomy or wedge resection (removal of part of the lobe of the lung). Cancers in some locations (such as where the windpipe divides into the left and right main bronchi) may be treated with a sleeve resection, but in some cases, they may be hard to remove completely without removing a lobe (lobectomy) or even an entire lung (pneumonectomy).

For some stage 0 cancers, treatments such as photodynamic therapy (PDT), laser therapy, or brachytherapy (internal radiation) may be alternatives to surgery.

Treating stage I NSCLC

If you have stage I NSCLC, surgery may be the only treatment you need. Surgery will either take out the lobe of the lung that has the tumor (lobectomy) or take out a smaller piece of the lung (sleeve resection, segmentectomy, or wedge resection). At least some lymph nodes in the lung and in the space between the lungs will also be removed and checked for cancer.

Segmentectomy or wedge resection is generally an option only for very small stage I cancers and for patients with other health problems that make removing the entire lobe dangerous. Still, most surgeons believe it is better to do a lobectomy if the patient can tolerate it, as it offers the best chance for cure.

For people with stage I NSCLC that has a higher risk of coming back (based on size, location, or other factors), chemotherapy, immunotherapy, and possibly targeted therapy (ie. alectinib, osimertinib) after surgery may lower the risk that cancer will return. This is called adjuvant treatment.

After surgery, the removed tissue is checked to see if there are cancer cells at the edges of the surgery specimen (called positive margins). This could mean that some cancer has been left behind, so a second surgery might be done to try to ensure that all the cancer has been removed (this might be followed by chemotherapy as well). Another option might be to use radiation therapy after surgery.

If you have serious health problems that prevent you from having surgery, you may get stereotactic body radiation therapy (SBRT) or another type of radiation therapy as your main treatment. Ablation may be another option if the tumor is small and you are not able to undergo surgery.

Treating stage II NSCLC

Neoadjuvant (pre-operative) chemotherapy with or without immunotherapy is usually offered to patients with stage II NSCLC. After neoadjuvant therapy, people who have stage II NSCLC and are healthy enough for surgery usually have the cancer removed by lobectomy or sleeve resection. Sometimes removing the whole lung (pneumonectomy) is needed.

Any lymph nodes likely to have cancer in them are also removed. The extent of lymph node involvement and whether or not cancer cells are found at the edges of the removed tissues are important factors when planning the next step of treatment.

After surgery, the removed tissue is checked to see if there are cancer cells at the edges of the surgery specimen. This might mean that some cancer has been left behind, so a second surgery might be done to try to remove any remaining cancer. This may be followed by additional treatment with either chemotherapy, targeted therapy (ie. alectinib, osimertinib), or immunotherapy (ie. nivolumab, atezolizumab, pembrolizumab, durvalumab). 

Treating stage IIIA NSCLC

The initial treatment for stage IIIA NSCLC may include some combination of radiation therapy, chemotherapy (chemo), immunotherapy, and/or surgery. For this reason, planning treatment for stage IIIA NSCLC often requires input from a medical oncologist, radiation oncologist, and a thoracic surgeon. Your treatment options depend on the size of the tumor, where it is in your lung, which lymph nodes it has spread to, your overall health, and how well you are tolerating treatment.

For stage IIIA lung cancers that is not able to be surgically removed, treatment usually starts with chemo, often combined with radiation therapy (called chemoradiation). After chemoradiation is completed, if the lung cancer has a certain EGFR mutation, adjuvant therapy with osimertinib may be recommended.

For certain stage IIIA cancers, surgery may be an option. Treatment usually starts with chemotherapy with or without immunotherapy or chemoradiation, followed by surgery, if the doctor thinks any remaining cancer can be removed and the patient is healthy enough. Additional therapy after surgery (adjuvant therapy) might be needed depending on what is found during surgery. Options for adjuvant therapy include chemotherapy, targeted therapy (ie. alectinib, osimertinib) and/or immunotherapy (ie. nivolumab).

If surgery, radiation, and chemoradiation are not likely to be good treatment options, treatment with an immunotherapy drug such as pembrolizumab (Keytruda) or cemiplimab (Libtayo) may be considered first.

Treating stage IIIB NSCLC

Stage IIIB NSCLC has spread to lymph nodes that are near the other lung or in the neck, and may also have grown into important structures in the chest. These cancers can’t be removed completely by surgery.

As with other stages of lung cancer, treatment depends on the patient’s overall health. If you are in fairly good health you may be helped by chemotherapy (chemo) combined with radiation therapy (known as chemoradiation). Additional therapy after chemoradiation may be needed such as targeted therapy (ie. Osimertinib if cancer cells have the EGFR mutation) or immunotherapy (ie. durvalumab, which can be given for up to a year to help keep the cancer stable).

Patients who are not healthy enough for this combination are often treated with radiation therapy alone, or, less often, chemo alone. If surgery, radiation, and chemoradiation aren’t likely to be good treatment options, an immunotherapy drug such as pembrolizumab (Keytruda) or cemiplimab (Libtayo) may be considered as the first treatment.

These cancers can be hard to treat, so taking part in a clinical trial of newer treatments may be a good option for some people.

Treating stage IVA and IVB NSCLC

Stage IVA or IVB NSCLC has already spread when it is diagnosed. These cancers can be very hard to cure. Treatment options depend on where and how far the cancer has spread, whether the cancer cells have certain gene or protein changes, and your overall health.

If you are in otherwise good health, treatments such as surgery, chemotherapy (chemo), targeted therapy, immunotherapy, and radiation therapy may help you live longer and make you feel better by relieving symptoms, even though they aren’t likely to cure you.

Other treatments, such as photodynamic therapy (PDT) or laser therapy, may also be used to help relieve symptoms. In any case, if you are going to be treated for advanced NSCLC, be sure you understand the goals of treatment before you start.

NSCLC that has spread to only one other site (stage IVA)

Cancer that is limited in the lungs and has only spread to one other site (such as the brain) is not common, but it can sometimes be treated (and even potentially cured) with surgery and/or radiation therapy to treat the area of cancer spread, followed by treatment of the cancer in the lung. For example, a single tumor in the brain may be treated with surgery or stereotactic radiation, or surgery followed by radiation to the whole brain. Treatment for the lung tumor is then based on its T and N stages, and may include surgery, chemo, radiation, or some of these in combination.

NSCLC that has spread widely (stage IVB)

For cancers that have spread widely throughout the body, before any treatments start, your tumor will be tested for certain gene mutations (such as in the KRAS, EGFR, ALK, ROS1, BRAF, RET, MET, or NTRK genes). If one of these genes is mutated in your cancer cells, your first treatment will likely be a targeted therapy drug.

Your tumor cells might also be tested for the PD-L1 protein. Tumors with higher levels of PD-L1 are more likely to respond to certain immunotherapy drugs (known as immune checkpoint inhibitors), which might be an option either alone or along with chemo.

If the cancer has caused fluid buildup in the space around the lungs (a malignant pleural effusion), the fluid may be drained. If it keeps coming back, options include pleurodesis or placement of a catheter into the chest through the skin to let the fluid drain out. (Details of these are discussed in Palliative Procedures for Non-Small Cell Lung Cancer.)

As with other stages, treatment for stage IV lung cancer depends on a person’s overall health. For example, some people not in good health might get only 1 chemo drug instead of 2. For people who can’t have chemo, radiation therapy is usually the treatment of choice. Local treatments such as laser therapy, PDT, or stent placement may also be used to help relieve symptoms caused by lung tumors.

Because treatment is unlikely to cure these cancers, taking part in a clinical trial of newer treatments may be a good option.

You can also find more information about living with stage IV cancer in Advanced Cancer.

NSCLC that progresses or recurs after treatment

If cancer continues to grow during treatment (progresses) or comes back (recurs), further treatment will depend on the location and extent of the cancer, what treatments have been used, and on the person’s health and desire for more treatment. It’s important to understand the goal of any further treatment – if it is to try to cure the cancer, to slow its growth, or to help relieve symptoms. It's also important to understand the benefits and risks.

Smaller cancers that recur locally in the lungs can sometimes be treated again with surgery or radiation therapy (if it hasn’t been used before).

Cancers that recur in the lymph nodes between the lungs are usually treated with chemo, possibly along with radiation if it hasn’t been used before.

For cancers that return at distant sites, chemo, targeted therapies, and/or immunotherapy are often the treatments of choice. A device that creates electric fields in the tumor might be an option, along with either immunotherapy or chemo.

For more on dealing with a recurrence, see Understanding Recurrence.

In some people, the cancer may never go away completely. These people may get regular treatments with chemo, radiation therapy, or other therapies to try to help keep the cancer in check. Learning to live with cancer that does not go away can be difficult and very stressful. It has its own type of uncertainty. Managing Cancer as a Chronic Illness talks more about this.

The American Cancer Society medical and editorial content team

Our team is made up of doctors and oncology certified nurses with deep knowledge of cancer care as well as editors and translators with extensive experience in medical writing.

Araujo LH, Horn L, Merritt RE, Shilo K, Xu-Welliver M, Carbone DP. Ch. 69 - Cancer of the Lung: Non-small cell lung cancer and small cell lung cancer. In: Niederhuber JE, Armitage JO, Doroshow JH, Kastan MB, Tepper JE, eds. Abeloff’s Clinical Oncology. 6th ed. Philadelphia, Pa: Elsevier; 2020.

Chiang A, Detterbeck FC, Stewart T, Decker RH, Tanoue L. Chapter 48: Non-small cell lung cancer. In: DeVita VT, Lawrence TS, Rosenberg SA, eds. DeVita, Hellman, and Rosenberg’s Cancer: Principles and Practice of Oncology. 11th ed. Philadelphia, Pa: Lippincott Williams & Wilkins; 2019.

National Cancer Institute. Physician Data Query (PDQ). Health Professional Version. Non-Small Cell Lung Cancer Treatment. 2023. Accessed at https://www.cancer.gov/types/lung/hp/non-small-cell-lung-treatment-pdq on Jan 23, 2024.

National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Non-Small Cell Lung Cancer. V.1.2024. Accessed at https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf on Jan 23, 2024.

Last Revised: October 29, 2024

American Cancer Society Emails

Sign up to stay up-to-date with news, valuable information, and ways to get involved with the American Cancer Society.